About Us Strategy & Mission Our Values Our People Our Board Our Collaborations Contact Our Programmes Overview Pipeline C. difficile Infection Gonorrhoea Enterobacteriaceae ESKAPE Programme Clinical Trials Stewardship Compassionate Use Our Science Discuva Platform Publications Investors Investor Centre Press Releases Financial Reports & Filings Email Alerts Events & Presentations Share Price Data Analyst Coverage Corporate Governance Shareholder Meetings Careers
Press Releases Our latest press releases are available to read in this section Press Releases Date Range Explore Search Press Releases / 07 Jan 2020 Summit Therapeutics Launches Online Resource for Patients with C. difficile Infection Press Releases / 17 Dec 2019 Financial Results for the Third Quarter Ended 31 October 2019 Press Releases / 17 Dec 2019 Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended 31 October 2019 Press Releases / 06 Dec 2019 Summit Announces a Proposed Subscription and Placing to Raise approximately $50.0 Million and Notice of General Meeting Press Releases / 06 Nov 2019 Summit Therapeutics to Participate in Panel Sessions at the World Antimicrobial Resistance Congress Press Releases / 04 Nov 2019 Summit Therapeutics Recognises C. difficile Awareness Month Press Releases / 16 Oct 2019 Summit Therapeutics to Present at the 2019 BIO Investor Forum Press Releases / 11 Oct 2019 Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended 31 July 2019 Press Releases / 07 Oct 2019 Summit Therapeutics Reports New Data from Phase 2 Clinical Trial Connecting Ridinilazole’s Microbiome Preservation to Improved Clinical Outcomes for Patients with C. difficile Infection Press Releases / 03 Oct 2019 Summit Therapeutics Reports Ridinilazole Significantly Improved Short and Longer-Term Quality of Life Measures in Patients with C. difficile Infection Compared to Standard of Care Press Releases / 25 Sep 2019 Summit to Host R&D Day 7 October 2019 Press Releases / 24 Sep 2019 Summit Therapeutics to Present Data from Phase 2 Clinical Trial of Ridinilazole at ID Week 2019 << 1 2 3 … 27 28 >>
Press Releases / 07 Jan 2020 Summit Therapeutics Launches Online Resource for Patients with C. difficile Infection Press Releases / 17 Dec 2019 Financial Results for the Third Quarter Ended 31 October 2019 Press Releases / 17 Dec 2019 Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended 31 October 2019 Press Releases / 06 Dec 2019 Summit Announces a Proposed Subscription and Placing to Raise approximately $50.0 Million and Notice of General Meeting Press Releases / 06 Nov 2019 Summit Therapeutics to Participate in Panel Sessions at the World Antimicrobial Resistance Congress Press Releases / 04 Nov 2019 Summit Therapeutics Recognises C. difficile Awareness Month Press Releases / 16 Oct 2019 Summit Therapeutics to Present at the 2019 BIO Investor Forum Press Releases / 11 Oct 2019 Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended 31 July 2019 Press Releases / 07 Oct 2019 Summit Therapeutics Reports New Data from Phase 2 Clinical Trial Connecting Ridinilazole’s Microbiome Preservation to Improved Clinical Outcomes for Patients with C. difficile Infection Press Releases / 03 Oct 2019 Summit Therapeutics Reports Ridinilazole Significantly Improved Short and Longer-Term Quality of Life Measures in Patients with C. difficile Infection Compared to Standard of Care Press Releases / 25 Sep 2019 Summit to Host R&D Day 7 October 2019 Press Releases / 24 Sep 2019 Summit Therapeutics to Present Data from Phase 2 Clinical Trial of Ridinilazole at ID Week 2019
Press Releases / 07 Jan 2020 Summit Therapeutics Launches Online Resource for Patients with C. difficile Infection
Press Releases / 17 Dec 2019 Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended 31 October 2019
Press Releases / 06 Dec 2019 Summit Announces a Proposed Subscription and Placing to Raise approximately $50.0 Million and Notice of General Meeting
Press Releases / 06 Nov 2019 Summit Therapeutics to Participate in Panel Sessions at the World Antimicrobial Resistance Congress
Press Releases / 11 Oct 2019 Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended 31 July 2019
Press Releases / 07 Oct 2019 Summit Therapeutics Reports New Data from Phase 2 Clinical Trial Connecting Ridinilazole’s Microbiome Preservation to Improved Clinical Outcomes for Patients with C. difficile Infection
Press Releases / 03 Oct 2019 Summit Therapeutics Reports Ridinilazole Significantly Improved Short and Longer-Term Quality of Life Measures in Patients with C. difficile Infection Compared to Standard of Care
Press Releases / 24 Sep 2019 Summit Therapeutics to Present Data from Phase 2 Clinical Trial of Ridinilazole at ID Week 2019
